KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Operations (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Cash from Operations for 8 consecutive years, with 45243000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 229.44% year-over-year to 45243000.0, compared with a TTM value of 13093000.0 through Dec 2025, up 44.65%, and an annual FY2025 reading of 13093000.0, up 44.65% over the prior year.
  • Cash from Operations was 45243000.0 for Q4 2025 at Esperion Therapeutics, up from 4286000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 53828000.0 in Q1 2024 and bottomed at 89068000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 30543500.0, with a median of 36190500.0 recorded in 2023.
  • Peak annual rise in Cash from Operations hit 229.44% in 2025, while the deepest fall reached 336.11% in 2025.
  • Year by year, Cash from Operations stood at 57706000.0 in 2021, then rose by 26.4% to 42472000.0 in 2022, then grew by 12.75% to 37056000.0 in 2023, then rose by 5.68% to 34952000.0 in 2024, then skyrocketed by 229.44% to 45243000.0 in 2025.
  • Business Quant data shows Cash from Operations for ESPR at 45243000.0 in Q4 2025, 4286000.0 in Q3 2025, and 31422000.0 in Q2 2025.